Fbxw7α-and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma

Nature Cell Biology

Volumn 14, Issue 4, 2012, Pages 375-385

  Busino, Luca ^a   Millman, Scott E ^a   Scotto, Luigi ^a   Kyratsous, Christos A ^a,b,e   Basrur, Venkatesha ^c   O'Connor, Owen ^a   Hoffmann, Alexander ^d   Elenitoba Johnson, Kojo S ^c   Pagano, Michele ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

F BOX PROTEIN; F BOX WD40 REPEAT CONTAINING PROTEIN 7; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

CELL CYCLE PROTEINS; CELL SURVIVAL; F-BOX PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HELA CELLS; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B P52 SUBUNIT; TUMOR CELLS, CULTURED; UBIQUITIN-PROTEIN LIGASES;

EID: 84859430011     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2463     Document Type: Article

References (48)

1. Skaar, J. R., D'Angiolella, V., Pagan, J. K. & Pagano, M. S. F box proteins II. Cell 137, e1351-e1358 (2009).
2. Cardozo, T. & Pagano, M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5, 739-751 (2004). (Pubitemid 39208183)
3. Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6, 9-20 (2005). (Pubitemid 40064895)
4. Hoeck, J. D. et al. Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat. Neurosci. 13, 1365-1372 (2010).
5. Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83-93 (2008). (Pubitemid 351161321)
6. Onoyama, I. et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 204, 2875-2888 (2007). (Pubitemid 350179557)
7. Thompson, B. J. et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007). (Pubitemid 47236320)
8. Rajagopalan, H. et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77-81 (2004). (Pubitemid 38332360)
9. Millman, S. E. & Pagano, M. MCL1 meets its end during mitotic arrest. EMBO Rep. 12, 384-385 (2011).
10. Mavrakis, K. J. et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat. Genet. 43, 673-678 (2011).
11. O'Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007). (Pubitemid 47236319)
12. Akhoondi, S. et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67, 9006-9012 (2007). (Pubitemid 47535882)
13. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
14. Ghosh, S. & Karin, M. Missing pieces in the NF-2B puzzle. Cell 109 Suppl., S81-S96 (2002).
15. Senftleben, U. et al. Activation by IKK of a second, evolutionary conserved, NF-2B signaling pathway. Science 293, 1495-1499 (2001). (Pubitemid 32801552)
16. Dejardin, E. et al. The lymphotoxin-receptor induces different patterns of gene expression via two NF-2B pathways. Immunity 17, 525-535 (2002). (Pubitemid 35223540)
17. Coope, H. J. et al. CD40 regulates the processing of NF-2B2 p100 to p52. EMBO J. 21, 5375-5385 (2002). (Pubitemid 35231017)
18. Weih, F. & Caamano, J. Regulation of secondary lymphoid organ development by the nuclear factor-B signal transduction pathway. Immunol. Rev. 195, 91-105 (2003).
19. Ramakrishnan, P., Wang, W. & Wallach, D. Receptor-specific signaling for both the alternative and the canonical NF-2B activation pathways by NF-2B-inducing kinase. Immunity 21, 477-489 (2004). (Pubitemid 39370504)
20. Zarnegar, B. et al. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-2B activation pathways. Proc. Natl Acad. Sci. USA 101, 8108-8113 (2004). (Pubitemid 38698062)
21. Basak, S. et al. A fourth IB protein within the NF-2B signaling module. Cell 128, 369-381 (2007). (Pubitemid 46123518)
22. Mordmuller, B., Krappmann, D., Esen, M., Wegener, E. & Scheidereit, C. Lymphotoxin and lipopolysaccharide induce NF-2B-p52 generation by a co-translational mechanism. EMBO Rep. 4, 82-87 (2003). (Pubitemid 36305383)
23. Xiao, G., Harhaj, E. W. & Sun, S. C. NF-2B-inducing kinase regulates the processing of NF-2B2 p100. Mol. Cell 7, 401-409 (2001). (Pubitemid 32206507)
24. Fong, A. & Sun, S. C. Genetic evidence for the essential role of transducin repeat-containing protein in the inducible processing of NF-2B2/p100. J. Biol. Chem. 277, 22111-22114 (2002). (Pubitemid 34967173)
25. Bonizzi, G. et al. Activation of IKK target genes depends on recognition of specific B binding sites by RelB:p52 dimers. EMBO J. 23, 4202-4210 (2004). (Pubitemid 39546158)
26. Muller, J. R. & Siebenlist, U. Lymphotoxin receptor induces sequential activation of distinct NF-2B factors via separate signaling pathways. J. Biol. Chem. 278, 12006-12012 (2003). (Pubitemid 36800176)
27. Staudt, L. M. Oncogenic activation of NF-2B. Cold Spring Harb. Perspect Biol. 2, a000109 (2010).
28. Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-2B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007). (Pubitemid 47199123)
29. Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-2B pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007). (Pubitemid 47208626)
30. Razani, B. et al. Negative feedback in noncanonical NF-2B signaling modulates NIK stability through IKK-mediated phosphorylation. Sci. Signal. 3, ra41 (2010).
31. Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W. & Pavletich, N. P. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131-143 (2007). (Pubitemid 46550934)
32. Orian, A. et al. SCF (f)(-TrCP) ubiquitin ligase-mediated processing of NF-2B p105 requires phosphorylation of its C-terminus by IB kinase. EMBO J. 19, 2580-2591 (2000). (Pubitemid 30323547)
33. Sato, N., Meijer, L., Skaltsounis, L., Greengard, P. & Brivanlou, A. H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55-63 (2004). (Pubitemid 38524699)
34. Solan, N. J., Miyoshi, H., Carmona, E. M., Bren, G. D. & Paya, C. V. RelB cellular regulation and transcriptional activity are regulated by p100. J. Biol. Chem. 277, 1405-1418 (2002). (Pubitemid 34968896)
35. van Drogen, F. et al. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol. Cell 23, 37-48 (2006).
36. Sangfelt, O., Cepeda, D., Malyukova, A., van Drogen, F. & Reed, S. I. Both SCF(Cdc4) and SCF(Cdc4) are required for cyclin E turnover in cell lines that do not overexpress cyclin E. Cell Cycle 7, 1075-1082 (2008).
37. Derudder, E. et al. RelB/p50 dimers are differentially regulated by tumor necrosis factor-and lymphotoxin-receptor activation: critical roles for p100. J. Biol. Chem. 278, 23278-23284 (2003). (Pubitemid 36830141)
38. Shih, V. F. et al. Kinetic control of negative feedback regulators of NF-2B=RelA determines their pathogen-and cytokine-receptor signaling specificity. Proc. Natl Acad. Sci. USA 106, 9619-9624 (2009).
39. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl. J. Med. 352, 2487-2498 (2005). (Pubitemid 41007864)
40. Shah, J. J. et al. Phase 1 dose-escalation study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-Hodgkin lymphoma. Blood 114, 735-736 (2009).
41. Thompson, B. J. et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J. Exp. Med. 205, 1395-1408 (2008). (Pubitemid 351831495)
42. Xie, P., Stunz, L. L., Larison, K. D., Yang, B. & Bishop, G. A. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 27, 253-267 (2007). (Pubitemid 47284931)
43. Hoêich, K. P. et al. Requirement for glycogen synthase kinase-3 in cell survival and NF-2B activation. Nature 406, 86-90 (2000). (Pubitemid 30460216)
44. Milhollen, M. A. et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-2B-dependent lymphoma. Blood 116, 1515-1523 (2010).
45. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
46. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
47. Busino, L. et al. Degradation of Cdc25A by-TrCP during S phase and in response to DNA damage. Nature 426, 87-91 (2003). (Pubitemid 37432546)
48. Busino, L. et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316, 900-904 (2007). (Pubitemid 46764282)